Levetiracetam (Keppra) vs Levetiracetam (Keppra XR)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Epilepsy

Shared mechanism: Synaptic vesicle protein 2A (SV2A) · full Epilepsy pipeline

Levetiracetam (Keppra)

Marketed by UCB

Approved in Epilepsysmall molecule
Partial signal

NCT00150709 · Phase 3 · completed

This was a non-randomized, open-label extension study in which all children continued on levetiracetam after completing earlier pediatric levetiracetam trials. It reports descriptive seizure-frequency changes (e.g., median ~66% reduction in partial seizures among prior placebo-treated patients) over roughly two years, but with no control group and no formal statistical comparison. Because it is a genuine roll-over of previously randomized trial participants, it offers real longitudinal data but only moderate-strength evidence.

Next expected readout: February 2029 · NCT07130786 (registry estimate)

Reported efficacy

Percentage Change From Baseline in Partial Onset (Type I) Seizure Frequency Per Week Over Time During the Treatment Period (During the Treatment Period (an average of 2 years), compared to Baseline); Percentage Change From Baseline in Total (Type I, II, III) Seizure Frequency Per Week Over Time During the Treatment Period (During the Treatment Period (an average of 2 years), compared to Baseline): Percentage Change From Baseline in Partial Onset (Type I) Seizure Frequency Per Week Over Time During the Treatment Period (During the Treatment Period (an average of 2 years), compared to Baseline): N159 PBO/LEV -66.4 percentage of change (IQR -90 to -22.3) | N159 LEV/LEV -47.8 percentage of change (IQR -76.2 to -25.4) | N01010+N151 LEV/LEV -66.4 percentage of change (IQR -93.6 to -5.6) (not_applicable)

Result source: NCT00150709

Levetiracetam (Keppra XR)

Marketed by UCB

Approved in Epilepsysmall molecule
Partial signal

NCT00419094 · Phase 3 · completed

This randomized, triple-blind Phase 3 trial assigned 228 participants with partial-onset seizures to Keppra XR 2000 mg/day or 1000 mg/day in a 3:1 ratio during conversion to monotherapy. The primary endpoint was the cumulative rate of seizure-related exit at Day 112, tested in the 2000 mg/day group only against a historical control rate of 0.678. The exit rate was 0.375 (95% CI 0.297 to 0.453), so the prespecified criterion was met; the comparison relied on a historical benchmark because the trial had no concurrent placebo or active control arm.

Reported efficacy

The Cumulative Exit Rate at 112 Days After the Beginning of the Previous Antiepileptic Drug (AED) Tapering Phase: The Cumulative Exit Rate at 112 Days After the Beginning of the Previous Antiepileptic Drug (AED) Tapering Phase (112 days): Keppra XR 2000 mg/Day 37.5% (95% CI 29.7% to 45.3%) (met)

Result source: NCT00419094

Results for Epilepsy

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLevetiracetam (Keppra)Levetiracetam (Keppra XR)
Seizure frequency, % change—Not posted · NCT00160550—Not reported
50% responder rate—Not posted · NCT00160550—Not reported
Seizure freedom—Not posted · NCT00160550—Not reported

Seizure frequency, % change

Levetiracetam (Keppra)
—Not posted · NCT00160550
Levetiracetam (Keppra XR)
—Not reported

50% responder rate

Levetiracetam (Keppra)
—Not posted · NCT00160550
Levetiracetam (Keppra XR)
—Not reported

Seizure freedom

Levetiracetam (Keppra)
—Not posted · NCT00160550
Levetiracetam (Keppra XR)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Levetiracetam (Keppra): 4 of 4 rows · Levetiracetam (Keppra XR): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLevetiracetam (Keppra)Levetiracetam (Keppra XR)
Dropout rate
58.5%N01010+N151 LEV/LEVa
NCT00150709 · Phase 3 · monotherapy
show 32 more results
57.1%N01052 LEV/LEV
NCT00150709 · Phase 3 · monotherapy
69.7%N159 LEV/LEV
NCT00150709 · Phase 3 · monotherapy
69.6%N159 PBO/LEV
NCT00150709 · Phase 3 · monotherapy
15.6%Levetiracetam: Adjunctive Therapy
NCT03340064 · Phase 3 · combination
0%Levetiracetam: Monotherapy
NCT03340064 · Phase 3 · monotherapy
37.3%
NCT01229735 · Phase 4 · registry result, not featured evidence
—
NCT00855738 · Phase 4 · registry result, not featured evidence
38.2%
NCT00510783 · Phase 4 · registry result, not featured evidence
33.3%
NCT01318408 · Phase 4 · registry result, not featured evidence
13.1%
NCT00160654 · Phase 4 · registry result, not featured evidence
—
NCT01398956 · Phase 3 · registry result, not featured evidence
—
NCT01954121 · Phase 3 · registry result, not featured evidence
70%3000 mg/Day
NCT01506882 · Phase 3 · registry result, not featured evidence
36.1%1000 mg/Day to 2000 mg/Day
NCT01506882 · Phase 3 · registry result, not featured evidence
25%
NCT01345058 · Phase 3 · registry result, not featured evidence · combination
35.7%
NCT01228747 · Phase 3 · registry result, not featured evidence
15.1%
NCT01063764 · Phase 3 · registry result, not featured evidence
15.4%
NCT01292837 · Phase 3 · registry result, not featured evidence
—
NCT00367432 · Phase 3 · registry result, not featured evidence
29.4%
NCT00152516 · Phase 3 · registry result, not featured evidence
11.5%
NCT00291655 · Phase 3 · registry result, not featured evidence
27.3%
NCT00150813 · Phase 3 · registry result, not featured evidence
44.6%N165 Randomized Treatment LEV
NCT00160615 · Phase 3 · registry result, not featured evidence
—N165 Randomized Treatment LEV (FAS
NCT00160615 · Phase 3 · registry result, not featured evidence
4.3%
NCT01982812 · Phase 2 · registry result, not featured evidence
0%
NCT01407523 · Phase 2 · registry result, not featured evidence
15.8%
NCT00505934 · Phase 2 · registry result, not featured evidence
0%
NCT00535392 · Phase 2 · registry result, not featured evidence
10.6%
NCT01463033 · Phase 2 · registry result, not featured evidence
6.3%
NCT01720667 · Phase 1/2 · registry result, not featured evidence
0%High Dose
NCT00884052 · Phase 1/2 · registry result, not featured evidence
0%Low Dose
NCT00884052 · Phase 1/2 · registry result, not featured evidence
17.5%2000 mg/daya
NCT00419094 · Phase 3
show 5 more results
12.3%1000 mg/day
NCT00419094 · Phase 3
10.1%
NCT00368069 · Phase 3
12.6%
NCT00419393 · Phase 3 · registry result, not featured evidence
0%Keppra XR in Adults (18-55 Years O
NCT00961441 · Phase 2 · registry result, not featured evidence
0%Keppra XR in Children (12-16 Years
NCT00961441 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
4.9%N01010+N151 LEV/LEVa
NCT00150709 · Phase 3 · monotherapy
show 32 more results
21.4%N01052 LEV/LEV
NCT00150709 · Phase 3 · monotherapy
2.2%N159 LEV/LEV
NCT00150709 · Phase 3 · monotherapy
10.1%N159 PBO/LEV
NCT00150709 · Phase 3 · monotherapy
6.3%Levetiracetam: Adjunctive Therapy
NCT03340064 · Phase 3 · combination
0%Levetiracetam: Monotherapy
NCT03340064 · Phase 3 · monotherapy
—
NCT01229735 · Phase 4 · registry result, not featured evidence
—
NCT00855738 · Phase 4 · registry result, not featured evidence
—
NCT00510783 · Phase 4 · registry result, not featured evidence
—
NCT01318408 · Phase 4 · registry result, not featured evidence
5.6%
NCT00160654 · Phase 4 · registry result, not featured evidence
—
NCT01398956 · Phase 3 · registry result, not featured evidence
—
NCT01954121 · Phase 3 · registry result, not featured evidence
—3000 mg/Day
NCT01506882 · Phase 3 · registry result, not featured evidence
—1000 mg/Day to 2000 mg/Day
NCT01506882 · Phase 3 · registry result, not featured evidence
—
NCT01345058 · Phase 3 · registry result, not featured evidence · combination
3.2%
NCT01228747 · Phase 3 · registry result, not featured evidence
5.5%
NCT01063764 · Phase 3 · registry result, not featured evidence
7.7%
NCT01292837 · Phase 3 · registry result, not featured evidence
—
NCT00367432 · Phase 3 · registry result, not featured evidence
7.1%
NCT00152516 · Phase 3 · registry result, not featured evidence
—
NCT00291655 · Phase 3 · registry result, not featured evidence
1.5%
NCT00150813 · Phase 3 · registry result, not featured evidence
11.9%N165 Randomized Treatment LEV
NCT00160615 · Phase 3 · registry result, not featured evidence
—N165 Randomized Treatment LEV (FAS
NCT00160615 · Phase 3 · registry result, not featured evidence
0%
NCT01982812 · Phase 2 · registry result, not featured evidence
—
NCT01407523 · Phase 2 · registry result, not featured evidence
5.3%
NCT00505934 · Phase 2 · registry result, not featured evidence
—
NCT00535392 · Phase 2 · registry result, not featured evidence
—
NCT01463033 · Phase 2 · registry result, not featured evidence
1.6%
NCT01720667 · Phase 1/2 · registry result, not featured evidence
—High Dose
NCT00884052 · Phase 1/2 · registry result, not featured evidence
—Low Dose
NCT00884052 · Phase 1/2 · registry result, not featured evidence
4.1%2000 mg/daya
NCT00419094 · Phase 3
show 5 more results
5.3%1000 mg/day
NCT00419094 · Phase 3
6.3%
NCT00368069 · Phase 3
2.6%
NCT00419393 · Phase 3 · registry result, not featured evidence
—Keppra XR in Adults (18-55 Years O
NCT00961441 · Phase 2 · registry result, not featured evidence
—Keppra XR in Children (12-16 Years
NCT00961441 · Phase 2 · registry result, not featured evidence
Serious AEs
29.3%N01010+N151 LEV/LEVa
NCT00150709 · Phase 3 · monotherapy
show 32 more results
50%N01052 LEV/LEV
NCT00150709 · Phase 3 · monotherapy
39.3%N159 LEV/LEV
NCT00150709 · Phase 3 · monotherapy
25.3%N159 PBO/LEV
NCT00150709 · Phase 3 · monotherapy
56.3%Levetiracetam: Adjunctive Therapy
NCT03340064 · Phase 3 · combination
33.3%Levetiracetam: Monotherapy
NCT03340064 · Phase 3 · monotherapy
5.6%
NCT01229735 · Phase 4 · registry result, not featured evidence
0%
NCT00855738 · Phase 4 · registry result, not featured evidence
0%
NCT00510783 · Phase 4 · registry result, not featured evidence
0%
NCT01318408 · Phase 4 · registry result, not featured evidence
6%
NCT00160654 · Phase 4 · registry result, not featured evidence
29.5%
NCT01398956 · Phase 3 · registry result, not featured evidence
4.1%
NCT01954121 · Phase 3 · registry result, not featured evidence
20%3000 mg/Day
NCT01506882 · Phase 3 · registry result, not featured evidence
13.1%1000 mg/Day to 2000 mg/Day
NCT01506882 · Phase 3 · registry result, not featured evidence
0%
NCT01345058 · Phase 3 · registry result, not featured evidence · combination
0.8%
NCT01228747 · Phase 3 · registry result, not featured evidence
11%
NCT01063764 · Phase 3 · registry result, not featured evidence
0%
NCT01292837 · Phase 3 · registry result, not featured evidence
16.1%
NCT00367432 · Phase 3 · registry result, not featured evidence
18%
NCT00152516 · Phase 3 · registry result, not featured evidence
4.6%
NCT00291655 · Phase 3 · registry result, not featured evidence
6.1%
NCT00150813 · Phase 3 · registry result, not featured evidence
—N165 Randomized Treatment LEV
NCT00160615 · Phase 3 · registry result, not featured evidence
21.8%N165 Randomized Treatment LEV (FAS
NCT00160615 · Phase 3 · registry result, not featured evidence
21.7%
NCT01982812 · Phase 2 · registry result, not featured evidence
0%
NCT01407523 · Phase 2 · registry result, not featured evidence
21.1%
NCT00505934 · Phase 2 · registry result, not featured evidence
9.1%
NCT00535392 · Phase 2 · registry result, not featured evidence
27.3%
NCT01463033 · Phase 2 · registry result, not featured evidence
1.6%
NCT01720667 · Phase 1/2 · registry result, not featured evidence
—High Dose
NCT00884052 · Phase 1/2 · registry result, not featured evidence
—Low Dose
NCT00884052 · Phase 1/2 · registry result, not featured evidence
7%2000 mg/daya
NCT00419094 · Phase 3
show 5 more results
3.5%1000 mg/day
NCT00419094 · Phase 3
7.8%
NCT00368069 · Phase 3
11.6%
NCT00419393 · Phase 3 · registry result, not featured evidence
0%Keppra XR in Adults (18-55 Years O
NCT00961441 · Phase 2 · registry result, not featured evidence
0%Keppra XR in Children (12-16 Years
NCT00961441 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
infection 48.8%
headache 36.6%
nervousness 34.1%
NCT00150709 · Phase 3 · monotherapy
show 28 more results
infection 71.4%
fever 50%
otitis media 50%
NCT00150709 · Phase 3 · monotherapy
infection 53.9%
accidental injury 29.2%
fever 25.8%
NCT00150709 · Phase 3 · monotherapy
infection 58.2%
fever 30.4%
pharyngitis 26.6%
NCT00150709 · Phase 3 · monotherapy
nasopharyngitis 53.1%
pyrexia 37.5%
eczema 28.1%
NCT03340064 · Phase 3 · combination
nasopharyngitis 83.3%
epistaxis 50%
hand-foot-and-mouth disease 50%
NCT03340064 · Phase 3 · monotherapy
somnolence 20.3%
dizziness 16.9%
nasopharyngitis 13.6%
NCT01229735 · Phase 4 · registry result, not featured evidence
somnolence 7.5%
weight increased 5%
dizziness 2.5%
NCT00855738 · Phase 4 · registry result, not featured evidence
dizziness 9.2%
fatigue 9.2%
burning at the iv site 6.6%
NCT00510783 · Phase 4 · registry result, not featured evidence
fatigue 16.7%
NCT01318408 · Phase 4 · registry result, not featured evidence
somnolence 29.9%
dizziness 14.3%
headache 6.4%
NCT00160654 · Phase 4 · registry result, not featured evidence
nasopharyngitis 79.5%
convulsion 36.4%
dental caries 25%
NCT01398956 · Phase 3 · registry result, not featured evidence
nasopharyngitis 18.3%
dizziness 15.1%
somnolence 9.2%
NCT01954121 · Phase 3 · registry result, not featured evidence
3000 mg/Day
nasopharyngitis 40%
diarrhoea 20%
head injury 20%
NCT01506882 · Phase 3 · registry result, not featured evidence
1000 mg/Day to 2000 mg/Day
nasopharyngitis 77%
somnolence 41%
malaise 19.7%
NCT01506882 · Phase 3 · registry result, not featured evidence
erectile dysfunction 11.1%
fatigue 11.1%
memory/cognitive difficulties/confusion 11.1%
NCT01345058 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 19% (placebo 16%)
protein urine present 7.9% (placebo 0.8%)
platelet count decreased 5.6% (placebo 3.2%)
NCT01228747 · Phase 3 · registry result, not featured evidence
nasopharyngitis 74%
somnolence 46.6%
influenza 27.4%
NCT01063764 · Phase 3 · registry result, not featured evidence
convulsion 23.1%
nasopharyngitis 23.1%
somnolence 23.1%
NCT01292837 · Phase 3 · registry result, not featured evidence
nasopharyngitis 77.4%
somnolence 39.9%
contusion 27.6%
NCT00367432 · Phase 3 · registry result, not featured evidence
pyrexia 31.8%
upper respiratory tract infection 24.3%
vomiting 16.1%
NCT00152516 · Phase 3 · registry result, not featured evidence
weight increased 5.4%
weight decreased 2.3%
NCT00291655 · Phase 3 · registry result, not featured evidence
nasopharyngitis 75.2% (placebo 76%)
contusion 28.7% (placebo 32%)
headache 27.7% (placebo 32%)
NCT00160615 · Phase 3 · registry result, not featured evidence
increased potassium 30.4%
increased phosphate 26.1%
increased ast 21.7%
NCT01982812 · Phase 2 · registry result, not featured evidence
arthralgia 6.3%
contusion 6.3%
gingivitis 6.3%
NCT01407523 · Phase 2 · registry result, not featured evidence
hypotension 10.5%
pyrexia 10.5%
bradycardia 5.3%
NCT00505934 · Phase 2 · registry result, not featured evidence
convulsion 9.1%
dry mouth 9.1%
hypotension 9.1%
NCT00535392 · Phase 2 · registry result, not featured evidence
fatigue 42.4%
headache 42.4%
drowsiness 30.3%
NCT01463033 · Phase 2 · registry result, not featured evidence
vasopressor requirement 15.6%
respiratory abnormality 12.5%
sedation 10.9%
NCT01720667 · Phase 1/2 · registry result, not featured evidence
2000 mg/daya
somnolence 22.2%
headache 18.7%
convulsion 11.7%
NCT00419094 · Phase 3
show 5 more results
1000 mg/day
headache 22.8%
somnolence 21.1%
convulsion 15.8%
NCT00419094 · Phase 3
influenza 7.8% (placebo 3.8%)
somnolence 7.8% (placebo 2.5%)
headache 6.5% (placebo 13.9%)
NCT00368069 · Phase 3
headache 13.8%
nasopharyngitis 7.9%
somnolence 7.9%
NCT00419393 · Phase 3 · registry result, not featured evidence
arthralgia 7.7%
dysmenorrhoea 7.7%
hypoaesthesia facial 7.7%
NCT00961441 · Phase 2 · registry result, not featured evidence
abnormal behaviour 8.3%
fatigue 8.3%
lymphadenopathy 8.3%
NCT00961441 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Levetiracetam (Keppra)

Seizure Frequency Change Per -2.1 per week
absolute change · per week
No placebo or comparator arm
NCT00150709 · Phase 3 · monotherapy
show 5 more results
-1.6 per week
NCT00150709 · Phase 3 · monotherapy
-1.5 per week
NCT00150709 · Phase 3 · monotherapy
-2.1 per week
NCT00150709 · Phase 3 · monotherapy
-1.5 per week
NCT00150709 · Phase 3 · monotherapy
-1.1 per week
NCT00150709 · Phase 3 · monotherapy
Seizure Frequency 50% 58.4% (n=77)
responder rate · % of participants
No placebo or comparator arm
NCT00150709 · Phase 3 · monotherapy
show 5 more results
47.7% (n=86)
NCT00150709 · Phase 3 · monotherapy
62.2% (n=37)
NCT00150709 · Phase 3 · monotherapy
58.4% (n=77)
NCT00150709 · Phase 3 · monotherapy
46.6% (n=88)
NCT00150709 · Phase 3 · monotherapy
62.2% (n=37)
NCT00150709 · Phase 3 · monotherapy
Seizure-free 7 93.7% (n=79)
event count · % of participants
No placebo or comparator arm
NCT00150709 · Phase 3 · monotherapy · converted to % from 74 Participants as posted
show 3 more results
82% (n=89)*
NCT00150709 · Phase 3 · monotherapy · converted to % from 73 Participants as posted
97.6% (n=41)*
NCT00150709 · Phase 3 · monotherapy · converted to % from 40 Participants as posted
71.4% (n=14)*
NCT00150709 · Phase 3 · monotherapy · converted to % from 10 Participants as posted
Continuous Seizure Free 74% (n=79) @ 0wk
responder rate · % of participants
Maintenance
No placebo or comparator arm
NCT00150709 · Phase 3 · monotherapy
show 43 more results
64% (n=89) @ 0wk
NCT00150709 · Phase 3 · monotherapy
75% (n=41) @ 0wk
NCT00150709 · Phase 3 · monotherapy
38.5% (n=14) @ 0wk
NCT00150709 · Phase 3 · monotherapy
16.4% (n=79) @ 8wk
NCT00150709 · Phase 3 · monotherapy
15.1% (n=89) @ 8wk
NCT00150709 · Phase 3 · monotherapy
27.5% (n=41) @ 8wk
NCT00150709 · Phase 3 · monotherapy
23.1% (n=14) @ 8wk
NCT00150709 · Phase 3 · monotherapy
12.3% (n=79) @ 16wk
NCT00150709 · Phase 3 · monotherapy
12.8% (n=89) @ 16wk
NCT00150709 · Phase 3 · monotherapy
17.5% (n=41) @ 16wk
NCT00150709 · Phase 3 · monotherapy
23.1% (n=14) @ 16wk
NCT00150709 · Phase 3 · monotherapy
11% (n=79) @ 24wk
NCT00150709 · Phase 3 · monotherapy
9.3% (n=89) @ 24wk
NCT00150709 · Phase 3 · monotherapy
15% (n=41) @ 24wk
NCT00150709 · Phase 3 · monotherapy
11.5% (n=14) @ 24wk
NCT00150709 · Phase 3 · monotherapy
8.2% (n=79) @ 32wk
NCT00150709 · Phase 3 · monotherapy
4.7% (n=89) @ 32wk
NCT00150709 · Phase 3 · monotherapy
12.5% (n=41) @ 32wk
NCT00150709 · Phase 3 · monotherapy
11.5% (n=14) @ 32wk
NCT00150709 · Phase 3 · monotherapy
5.5% (n=79) @ 40wk
NCT00150709 · Phase 3 · monotherapy
3.5% (n=89) @ 40wk
NCT00150709 · Phase 3 · monotherapy
10% (n=41) @ 40wk
NCT00150709 · Phase 3 · monotherapy
11.5% (n=14) @ 40wk
NCT00150709 · Phase 3 · monotherapy
1.4% (n=79) @ 48wk
NCT00150709 · Phase 3 · monotherapy
3.5% (n=89) @ 48wk
NCT00150709 · Phase 3 · monotherapy
7.5% (n=41) @ 48wk
NCT00150709 · Phase 3 · monotherapy
11.5% (n=14) @ 48wk
NCT00150709 · Phase 3 · monotherapy
1.4% (n=79) @ 56wk
NCT00150709 · Phase 3 · monotherapy
2.3% (n=89) @ 56wk
NCT00150709 · Phase 3 · monotherapy
5% (n=41) @ 56wk
NCT00150709 · Phase 3 · monotherapy
11.5% (n=14) @ 56wk
NCT00150709 · Phase 3 · monotherapy
1.4% (n=79) @ 64wk
NCT00150709 · Phase 3 · monotherapy
2.3% (n=89) @ 64wk
NCT00150709 · Phase 3 · monotherapy
5% (n=41) @ 64wk
NCT00150709 · Phase 3 · monotherapy
11.5% (n=14) @ 64wk
NCT00150709 · Phase 3 · monotherapy
1.4% (n=79) @ 72wk
NCT00150709 · Phase 3 · monotherapy
2.3% (n=89) @ 72wk
NCT00150709 · Phase 3 · monotherapy
2.5% (n=41) @ 72wk
NCT00150709 · Phase 3 · monotherapy
11.5% (n=14) @ 72wk
NCT00150709 · Phase 3 · monotherapy
1.4% (n=79) @ 80wk
NCT00150709 · Phase 3 · monotherapy
2.3% (n=89) @ 80wk
NCT00150709 · Phase 3 · monotherapy
2.5% (n=41) @ 80wk
NCT00150709 · Phase 3 · monotherapy
11.5% (n=14) @ 80wk
NCT00150709 · Phase 3 · monotherapy
Treatment Continuation 59.1% (n=176) vs 56.6% (n=166) Topiramate @ 52wk
responder rate · % of participants
NCT01229735 · Phase 4 · registry result, not featured evidence
Partial Onset Seizure Frequency -74.47% (n=174) vs -67.86% (n=165) Topiramate @ 52wk
percent change · % of baseline
NCT01229735 · Phase 4 · registry result, not featured evidence · converted to % from 74.47 percent reduction as posted
Partial Onset Seizure 120 vs 107 Topiramate responders @ 52wk
responder rate · responders
NCT01229735 · Phase 4 · registry result, not featured evidence
Seizure Recurrence 24 h 3.9% (n=76) vs 2.4% (n=82) Phenytoin/Fosphenytoin @ 0.142857wk
event count · % of participants
NCT00510783 · Phase 4 · registry result, not featured evidence · converted to % from 3 participants as posted
MMSE 2.2 score @ 13wk
absolute change · score
No placebo or comparator arm
NCT01318408 · Phase 4 · registry result, not featured evidence
ADAS-Cog -4.3 score @ 13wk
absolute change · score
No placebo or comparator arm
NCT01318408 · Phase 4 · registry result, not featured evidence
Partial Seizure Frequency -48.34% (n=237) @ 16wk
percent change · % of baseline
No placebo or comparator arm
NCT00160654 · Phase 4 · registry result, not featured evidence
show 3 more results
-43.21% (n=73) @ 22wk*
NCT01063764 · Phase 3 · registry result, not featured evidence · converted to % from 43.21 Percent reduction as posted
-39.02% (n=68) @ 22wk*
NCT01063764 · Phase 3 · registry result, not featured evidence · converted to % from 39.02 Percent reduction as posted
-41.32% (n=55)*
NCT01063764 · Phase 3 · registry result, not featured evidence · converted to % from 41.32 Percent reduction as posted
Total Seizure Frequency -46.43% (n=243) @ 16wk
percent change · % of baseline
No placebo or comparator arm
NCT00160654 · Phase 4 · registry result, not featured evidence

+ 45 further endpoints in the CSV export.

Levetiracetam (Keppra XR)

Clinical Failure 0.375% (n=158) @ 16wk2000 mg/day
event rate · % of participants
No placebo or comparator arm
NCT00419094 · Phase 3
show 1 more result
0.334% (n=54) @ 16wk1000 mg/day
NCT00419094 · Phase 3
Treatment Failure 0.385% (n=158) @ 16wk2000 mg/day
event count · % of participants
No placebo or comparator arm
NCT00419094 · Phase 3
All-Cause Discontinuation 0.475% (n=158) @ 16wk2000 mg/day
event count · % of participants
No placebo or comparator arm
NCT00419094 · Phase 3
Partial Onset Seizure Frequency Per 0.912 vs 1.067 placebo per week @ 12wk
absolute value · per week
NCT00368069 · Phase 3
show 1 more result
0.914 vs 1.119 placebo per week @ 12wk
NCT00368069 · Phase 3
Total Seizure Frequency 0.928 vs 1.086 placebo per week @ 12wk
absolute value · per week
NCT00368069 · Phase 3
Partial Seizure 43% (n=79) vs 29.1% (n=79) placebo @ 12wk
responder rate · % of participants
Response
NCT00368069 · Phase 3 · converted to % from 34 Participants as posted
Monotherapy Retention 77% (n=139) @ 26wk
responder rate · % of participants
No placebo or comparator arm
NCT00419393 · Phase 3 · registry result, not featured evidence
show 1 more result
65.3% (n=49) @ 52wk
NCT00419393 · Phase 3 · registry result, not featured evidence

Focal Onset Seizures

Shared mechanism: Synaptic vesicle protein 2A (SV2A) · full Focal Onset Seizures pipeline

Levetiracetam (Keppra)

Marketed by UCB

Approved in Focal Onset Seizuressmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Levetiracetam (Keppra XR)

Marketed by UCB

Approved in Focal Onset Seizuressmall molecule
Partial signal

NCT00419094 · Phase 3 · completed

This randomized, triple-blind Phase 3 trial assigned 228 participants with partial-onset seizures to Keppra XR 2000 mg/day or 1000 mg/day in a 3:1 ratio during conversion to monotherapy. The primary endpoint was the cumulative rate of seizure-related exit at Day 112, tested in the 2000 mg/day group only against a historical control rate of 0.678. The exit rate was 0.375 (95% CI 0.297 to 0.453), so the prespecified criterion was met; the comparison relied on a historical benchmark because the trial had no concurrent placebo or active control arm.

Reported efficacy

The Cumulative Exit Rate at 112 Days After the Beginning of the Previous Antiepileptic Drug (AED) Tapering Phase: The Cumulative Exit Rate at 112 Days After the Beginning of the Previous Antiepileptic Drug (AED) Tapering Phase (112 days): Keppra XR 2000 mg/Day 37.5% (95% CI 29.7% to 45.3%) (met)

Result source: NCT00419094

Results for Focal Onset Seizures

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

Coverage. Levetiracetam (Keppra): 4 of 4 rows · Levetiracetam (Keppra XR): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLevetiracetam (Keppra)Levetiracetam (Keppra XR)
Dropout rate
37.3%a
NCT01229735 · Phase 4 · registry result, not featured evidence
show 9 more results
—
NCT00855738 · Phase 4 · registry result, not featured evidence
—
NCT01954121 · Phase 3 · registry result, not featured evidence
70%3000 mg/Day
NCT01506882 · Phase 3 · registry result, not featured evidence
36.1%1000 mg/Day to 2000 mg/Day
NCT01506882 · Phase 3 · registry result, not featured evidence
—
NCT00367432 · Phase 3 · registry result, not featured evidence
29.4%
NCT00152516 · Phase 3 · registry result, not featured evidence
44.6%N165 Randomized Treatment LEV
NCT00160615 · Phase 3 · registry result, not featured evidence
—N165 Randomized Treatment LEV (FAS
NCT00160615 · Phase 3 · registry result, not featured evidence
0%
NCT01407523 · Phase 2 · registry result, not featured evidence
17.5%2000 mg/daya
NCT00419094 · Phase 3
show 1 more result
12.3%1000 mg/day
NCT00419094 · Phase 3
Discontinued due to AEs
—a
NCT01229735 · Phase 4 · registry result, not featured evidence
show 9 more results
—
NCT00855738 · Phase 4 · registry result, not featured evidence
—
NCT01954121 · Phase 3 · registry result, not featured evidence
—3000 mg/Day
NCT01506882 · Phase 3 · registry result, not featured evidence
—1000 mg/Day to 2000 mg/Day
NCT01506882 · Phase 3 · registry result, not featured evidence
—
NCT00367432 · Phase 3 · registry result, not featured evidence
7.1%
NCT00152516 · Phase 3 · registry result, not featured evidence
11.9%N165 Randomized Treatment LEV
NCT00160615 · Phase 3 · registry result, not featured evidence
—N165 Randomized Treatment LEV (FAS
NCT00160615 · Phase 3 · registry result, not featured evidence
—
NCT01407523 · Phase 2 · registry result, not featured evidence
4.1%2000 mg/daya
NCT00419094 · Phase 3
show 1 more result
5.3%1000 mg/day
NCT00419094 · Phase 3
Serious AEs
5.6%a
NCT01229735 · Phase 4 · registry result, not featured evidence
show 9 more results
0%
NCT00855738 · Phase 4 · registry result, not featured evidence
4.1%
NCT01954121 · Phase 3 · registry result, not featured evidence
20%3000 mg/Day
NCT01506882 · Phase 3 · registry result, not featured evidence
13.1%1000 mg/Day to 2000 mg/Day
NCT01506882 · Phase 3 · registry result, not featured evidence
16.1%
NCT00367432 · Phase 3 · registry result, not featured evidence
18%
NCT00152516 · Phase 3 · registry result, not featured evidence
—N165 Randomized Treatment LEV
NCT00160615 · Phase 3 · registry result, not featured evidence
21.8%N165 Randomized Treatment LEV (FAS
NCT00160615 · Phase 3 · registry result, not featured evidence
0%
NCT01407523 · Phase 2 · registry result, not featured evidence
7%2000 mg/daya
NCT00419094 · Phase 3
show 1 more result
3.5%1000 mg/day
NCT00419094 · Phase 3
Most frequent reported AEs
a
somnolence 20.3%
dizziness 16.9%
nasopharyngitis 13.6%
NCT01229735 · Phase 4 · registry result, not featured evidence
show 8 more results
somnolence 7.5%
weight increased 5%
dizziness 2.5%
NCT00855738 · Phase 4 · registry result, not featured evidence
nasopharyngitis 18.3%
dizziness 15.1%
somnolence 9.2%
NCT01954121 · Phase 3 · registry result, not featured evidence
3000 mg/Day
nasopharyngitis 40%
diarrhoea 20%
head injury 20%
NCT01506882 · Phase 3 · registry result, not featured evidence
1000 mg/Day to 2000 mg/Day
nasopharyngitis 77%
somnolence 41%
malaise 19.7%
NCT01506882 · Phase 3 · registry result, not featured evidence
nasopharyngitis 77.4%
somnolence 39.9%
contusion 27.6%
NCT00367432 · Phase 3 · registry result, not featured evidence
pyrexia 31.8%
upper respiratory tract infection 24.3%
vomiting 16.1%
NCT00152516 · Phase 3 · registry result, not featured evidence
nasopharyngitis 75.2% (placebo 76%)
contusion 28.7% (placebo 32%)
headache 27.7% (placebo 32%)
NCT00160615 · Phase 3 · registry result, not featured evidence
arthralgia 6.3%
contusion 6.3%
gingivitis 6.3%
NCT01407523 · Phase 2 · registry result, not featured evidence
2000 mg/daya
somnolence 22.2%
headache 18.7%
convulsion 11.7%
NCT00419094 · Phase 3
show 1 more result
1000 mg/day
headache 22.8%
somnolence 21.1%
convulsion 15.8%
NCT00419094 · Phase 3

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Levetiracetam (Keppra)

Treatment Continuation 59.1% (n=176) vs 56.6% (n=166) Topiramate @ 52wk
responder rate · % of participants
NCT01229735 · Phase 4 · registry result, not featured evidence
Partial Onset Seizure Frequency -74.47% (n=174) vs -67.86% (n=165) Topiramate @ 52wk
percent change · % of baseline
NCT01229735 · Phase 4 · registry result, not featured evidence · converted to % from 74.47 percent reduction as posted
Partial Onset Seizure 120 vs 107 Topiramate responders @ 52wk
responder rate · responders
NCT01229735 · Phase 4 · registry result, not featured evidence
Seizure Free 6 47.3% (n=186) vs 68.4% (n=171) Carbamazepine-IR @ 30wk
responder rate · % of participants
NCT01954121 · Phase 3 · registry result, not featured evidence
Time to First Seizure 87 vs 39 Carbamazepine-IR count @ 30wk
event count · count
NCT01954121 · Phase 3 · registry result, not featured evidence
show 1 more result
97 vs 57 Carbamazepine-IR count @ 30wk
NCT01954121 · Phase 3 · registry result, not featured evidence
Seizure Free 26 22.2% (n=9) @ 26wk3000 mg/Day
responder rate · % of participants
No placebo or comparator arm
NCT01506882 · Phase 3 · registry result, not featured evidence
show 1 more result
73.8% (n=61) @ 26wk1000 mg/Day to 2000 mg/Day
NCT01506882 · Phase 3 · registry result, not featured evidence
Seizure Free 12 11.1% (n=9) @ 52wk3000 mg/Day
responder rate · % of participants
Maintenance
No placebo or comparator arm
NCT01506882 · Phase 3 · registry result, not featured evidence
show 1 more result
59% (n=61) @ 52wk1000 mg/Day to 2000 mg/Day
NCT01506882 · Phase 3 · registry result, not featured evidence
Time to First Seizure 3.48 months3000 mg/Day
time to event · months
No placebo or comparator arm
NCT01506882 · Phase 3 · registry result, not featured evidence · converted to months from 106 days as posted
show 1 more result
NA months1000 mg/Day to 2000 mg/Day
NCT01506882 · Phase 3 · registry result, not featured evidence
Time to Discontinuation Any Reason Median 2.99 months3000 mg/Day
time to event · months
No placebo or comparator arm
NCT01506882 · Phase 3 · registry result, not featured evidence · converted to months from 91 days as posted
show 1 more result
NA months1000 mg/Day to 2000 mg/Day
NCT01506882 · Phase 3 · registry result, not featured evidence
Partial Onset Seizure Frequency -22% (n=313) @ 16wk
percent change · % of baseline
No placebo or comparator arm
NCT00367432 · Phase 3 · registry result, not featured evidence · converted to % from 22 Percent Reduction as posted
Partial Seizure Frequency -68.87 per week
absolute change · per week
Maintenance
No placebo or comparator arm
Maintenance
NCT00152516 · Phase 3 · registry result, not featured evidence · converted to per week from 68.87 percent reduction in seizures Per Week as posted
Seizure Frequency -66.02 per week
absolute change · per week
Maintenance
No placebo or comparator arm
Maintenance Period
NCT00152516 · Phase 3 · registry result, not featured evidence · converted to per week from 66.02 Percent Reduction in Seizures per Week as posted

+ 10 further endpoints in the CSV export.

Levetiracetam (Keppra XR)

Clinical Failure 0.375% (n=158) @ 16wk2000 mg/day
event rate · % of participants
No placebo or comparator arm
NCT00419094 · Phase 3
show 1 more result
0.334% (n=54) @ 16wk1000 mg/day
NCT00419094 · Phase 3
Treatment Failure 0.385% (n=158) @ 16wk2000 mg/day
event count · % of participants
No placebo or comparator arm
NCT00419094 · Phase 3
All-Cause Discontinuation 0.475% (n=158) @ 16wk2000 mg/day
event count · % of participants
No placebo or comparator arm
NCT00419094 · Phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Levetiracetam (Keppra)'s landscape · Levetiracetam (Keppra XR)'s landscape